{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:58:37Z","timestamp":1785913117292,"version":"3.56.0"},"reference-count":143,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>This review aims to point out the main achievements in the cutting-edge field of aptamer nanotechnology and its applications in the most frequent neuro-oncological and neurodegenerative diseases. The article discusses the properties, advantages and drawbacks of aptamers (AP), and their design and selection by various SELEX methods, as well as the synergical advantages as theranostics of the aptamer-functionalized nanoparticles (Ap-NP). The Ap-nanoconjugates properties are compared to those of Ap and unconjugated NP. Moreover, the article comparatively analyzes the aptamer-based approaches vs. antibody-drug conjugates vs. exosome-based delivery systems vs. unconjugated NP, as targeted therapies in neurodegenerative diseases and gliomas. The review presents major challenges in Ap-NP conjugates\u2019 clinical progress (concerning the in vivo enzymatic stability, blood\u2013brain barrier (BBB) permeability, selective intracellular uptake in the brain parenchyma and target tissues, rapid renal clearance, off-target toxicity, immunogenicity, reproductible manufacturing) and the investigated developmental strategies to solve them. Furthermore, relevant examples and comparative insights regarding preclinically tested Ap and Ap-NP conjugates are presented for targeted delivery systems loaded with chemotherapeutical drugs or genes, Ap-siRNA chimeras and immunotherapeutical aptamers, which are evaluated in glioblastomas (GBM), amyloidogenic diseases and multiple sclerosis (MS); radiotherapy enhancers in GBM; aptasensors for diagnostic and bioimaging-guided therapy in GBM, MS and amyloidopathies. The review finally points out future research directions in order to accelerate the clinical translation and the real-world impact as theranostics of the most preclinically advanced Ap-NP conjugates in major neuro-oncological and neurodegenerative disorders.<\/jats:p>","DOI":"10.3390\/pharmaceutics17091106","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:25:57Z","timestamp":1756189557000},"page":"1106","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aptamer-Nanoconjugates as Potential Theranostics in Major Neuro-Oncological and Neurodegenerative Disorders"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-4208","authenticated-orcid":false,"given":"Roxana-Georgiana","family":"Tauser","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-1863","authenticated-orcid":false,"given":"Florentina-Geanina","family":"Lupascu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1792-7139","authenticated-orcid":false,"given":"Bianca-Stefania","family":"Profire","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2530-3801","authenticated-orcid":false,"given":"Andreea-Teodora","family":"Iacob","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-2789","authenticated-orcid":false,"given":"Ioana-Mirela","family":"Vasincu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Apotrosoaei","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-1484","authenticated-orcid":false,"given":"Oana-Maria","family":"Chirliu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-7311","authenticated-orcid":false,"given":"Dan","family":"Lupascu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-3023","authenticated-orcid":false,"given":"Lenuta","family":"Profire","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy \u00abGrigore T. Popa\u00bb Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Koshmanova, A.A., Artyushenko, P.V., Shchugoreva, I.A., Fedotovskaya, V.D., Luzan, N.A., Kolovskaya, O.S., Zamay, G.S., Lukyanenko, K.A., Veprintsev, D.V., and Khilazheva, E.D. (2024). Aptamer\u2019s Structure Optimization for Better Diagnosis and Treatment of Glial Tumors. Cancers, 16.","DOI":"10.3390\/cancers16234111"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107967","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/IJN.S237544","article-title":"Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications","volume":"15","author":"Guan","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101350","DOI":"10.1016\/j.mam.2025.101350","article-title":"The recent blooming of therapeutic aptamers","volume":"102","author":"Cesarini","year":"2025","journal-title":"Mol. Aspects Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.yaoo.2017.03.004","article-title":"Anti-Vascular Endothelial Growth Factor Medications in Retinopathy of Prematurity","volume":"2","author":"Suelves","year":"2017","journal-title":"Adv. Ophthalmol. Optom."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bege, M., Ghanem, K.R., and Borb\u00e1s, A. (2025). The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy. Pharmaceutics., 17.","DOI":"10.3390\/pharmaceutics17030394"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/d41573-023-00148-z","article-title":"FDA approves second RNA aptamer","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wang, B., Kobeissy, F., Golpich, M., Cai, G., Li, X., Abedi, R., Haskins, W., Tan, W., Benner, S.A., and Wang, K.K.W. (2024). Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development. Molecules, 29.","DOI":"10.3390\/molecules29051124"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jelechem.2017.12.012","article-title":"Copper (II) oxide nanozyme based electrochemical cytosensor for high sensitive detection of circulating tumor cells in breast cancer","volume":"812","author":"Tian","year":"2018","journal-title":"J. Electroanal. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/neuonc\/noad156","article-title":"Aptamers in neuro-oncology: An emerging therapeutic modality","volume":"26","author":"Doherty","year":"2024","journal-title":"Neuro-Oncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107308","DOI":"10.1016\/j.phrs.2024.107308","article-title":"Brain gliomas: Diagnostic and therapeutic issues and the prospects of drug-targeted nano-delivery technology","volume":"206","author":"Song","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/cyto.a.22715","article-title":"Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma","volume":"87","author":"Motaln","year":"2015","journal-title":"Cytometry A"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Giles, B., Nakhjavani, M., Wiesa, A., Knight, T., Shigdar, S., and Samarasinghe, R.M. (2023). Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?. Cancers, 15.","DOI":"10.20944\/preprints202308.1054.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102699","DOI":"10.1016\/j.arr.2025.102699","article-title":"Hallmarks of Aging and Alzheimer\u2019s Disease Pathogenesis: Paving the Route for New Therapeutic Targets","volume":"106","author":"Bellelli","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as Therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.2174\/0929867326666191001125101","article-title":"Therapeutic Aptamers: Evolving to Find their Clinical Niche","volume":"27","author":"Nimjee","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sajid, M.I., Moazzam, M., Kato, S., Cho, K.Y., and Tiwari, R.K. (2020). Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100294"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/oli.2010.0264","article-title":"Cell-Specific Aptamer-Mediated Targeted Drug Delivery","volume":"21","author":"Zhou","year":"2011","journal-title":"Oligonucleotides"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.apsb.2024.03.034","article-title":"Monoclonal Antibodies and Aptamers: The Future Therapeutics for Alzheimer\u2019s Disease","volume":"14","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Murakami, K., Izuo, N., and Bitan, G. (2022). Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2021.101478"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1021\/acsptsci.2c00156","article-title":"Therapeutic Potential of Aptamer\u2013Protein Interactions","volume":"5","author":"Shraim","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e202402007","DOI":"10.1002\/anie.202402007","article-title":"Functional Selection of Tau Oligomerization\u2013Inhibiting Aptamers","volume":"63","author":"Wang","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_23","first-page":"127","article-title":"Nanozymes and aptamer-based biosensing","volume":"3","author":"Chatterjee","year":"2020","journal-title":"Mater. Sci. Energy Technol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Moreira, R., N\u00f3brega, C., De Almeida, L.P., and Mendon\u00e7a, L. (2024). Brain-targeted drug delivery\u2014Nanovesicles directed to specific brain cells by brain-targeting ligands. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02511-7"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jeevanandam, J., Tan, K.X., Danquah, M.K., Guo, H., and Turgeson, A. (2020). Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications-The Role of Molecular Dynamics Simulation. Biotechnol. J., 15.","DOI":"10.1002\/biot.201900368"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2308924","DOI":"10.1002\/advs.202308924","article-title":"Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono or Dual Targeted Proteins Degradation on Cell Surface","volume":"11","author":"Duan","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7150\/ntno.21638","article-title":"Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer","volume":"2","author":"Singh","year":"2018","journal-title":"Nanotheranostics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1021\/jacs.3c00841","article-title":"Aptamer-Based Targeted Delivery of Functional Nucleic Acids","volume":"145","author":"Xie","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Liu, M., Wang, L., Lo, Y., Shiu, S.C.-C., Kinghorn, A.B., and Tanner, J.A. (2022). Aptamer-Enabled Nanomaterials for Therapeutics, Drug Targeting and Imaging. Cells, 11.","DOI":"10.3390\/cells11010159"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Sung, H.J., Lee, Y.M., Choi, S.I., Kim, Y.H., Heo, K., and Kim, I.H. (2020). Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody). Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093286"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Shoemaker, R.L., Larsen, R.J., and Larsen, P.A. (2024). Single-Domain Antibodies and Aptamers Drive New Opportunities for Neurodegenerative Disease Research. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1426656"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118549","DOI":"10.1016\/j.molliq.2022.118549","article-title":"The application of exosomes and Exosome-nanoparticle in treating brain disorders","volume":"350","author":"Salarpour","year":"2022","journal-title":"J. Mol. Liq."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/acs.langmuir.1c02500","article-title":"Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy","volume":"38","author":"Liang","year":"2022","journal-title":"Langmuir"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2019.02.032","article-title":"Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward myelin as a platform for reducing multiple sclerosis clinical score","volume":"299","author":"Shamili","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.7150\/thno.85419","article-title":"Aptamer-engineered (nano)materials for theranostic applications","volume":"13","author":"Rabiee","year":"2023","journal-title":"Theranostics"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lin, R.-J. (2023). Evolution of Cell-Type-Specific RNA Aptamers via Live Cell-Based SELEX. RNA-Protein Complexes and Interactions, Springer.","DOI":"10.1007\/978-1-0716-3191-1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Meehan, C., Lecocq, S., and Penner, G. (2024). A reproducible approach for the use of aptamer libraries for the identification of Aptamarkers for brain amyloid deposition based on plasma analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0307678"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1007\/s12033-024-01256-w","article-title":"Enhanced SELEX Platforms for Aptamer Selection with Improved Characteristics: A Review","volume":"67","author":"Didarian","year":"2024","journal-title":"Mol. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shigdar, S., Agnello, L., Fedele, M., Camorani, S., and Cerchia, L. (2021). Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010028"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1039\/D2CB00231K","article-title":"A primer to directed evolution: Current methodologies and future directions","volume":"4","author":"Isalan","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"ref_43","unstructured":"(2025, February 13). Rtools. Available online: http:\/\/rtools.cbrc.jp\/."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Buglak, A.A., Samokhvalov, A.V., Zherdev, A.V., and Dzantiev, B.B. (2020). Methods and Applications of In Silico Aptamer Design and Modeling. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228420"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Joyce, T., Tasci, E., Jagasia, S., Shephard, J., Chappidi, S., Zhuge, Y., Zhang, L., Cooley Zgela, T., Sproull, M., and Mackey, M. (2024). Serum CD133-Associated Proteins Identified by Machine Learning Are Connected to Neural Development, Cancer Pathways, and 12-Month Survival in Glioblastoma. Cancers, 16.","DOI":"10.3390\/cancers16152740"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ymeth.2019.09.011","article-title":"RNA-centric approaches to study RNA-protein interactions in vitro and in silico","volume":"178","author":"Dasti","year":"2020","journal-title":"Methods"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"He, S., Du, Y., Tao, H., and Duan, H. (2023). Advances in aptamer-mediated targeted delivery system for cancer treatment. Int. J. Biol. Macromol., 238.","DOI":"10.1016\/j.ijbiomac.2023.124173"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wong, K.-Y., Wong, M.-S., and Liu, J. (2024). Aptamer-functionalized liposomes for drug delivery. Biomed. J., 47.","DOI":"10.1016\/j.bj.2023.100685"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1801362","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Amero, P., Khatua, S., Rodriguez-Aguayo, C., and Lopez-Berestein, G. (2020). Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers, 12.","DOI":"10.3390\/cancers12102889"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ismail, M., Liu, J., Wang, N., Zhang, D., Qin, C., Shi, B., and Zheng, M. (2025). Advanced nanoparticle engineering for precision therapeutics of brain diseases. Biomaterials, 318.","DOI":"10.1016\/j.biomaterials.2025.123138"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Khongkow, M., Yata, T., Boonrungsiman, S., Ruktanonchai, U.R., Graham, D., and Namdee, K. (2019). Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood-brain barrier penetration. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-44569-6"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"124800","DOI":"10.1016\/j.ijpharm.2024.124800","article-title":"Nanosystems for targeted drug Delivery: Innovations and challenges in overcoming the Blood-Brain barrier for neurodegenerative disease and cancer therapy","volume":"666","author":"Rafati","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2174\/1389557520666200513122357","article-title":"A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer\u2019s Disease","volume":"20","author":"Ghaffari","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Urmi, R., Banerjee, P., Singh, M., Singh, R., Chhillar, S., Sharma, N., Chandra, A., Singh, N., and Qamar, I. (2024). Revolutionizing biomedicine: Aptamer-based nanomaterials and nanodevices for therapeutic applications. Biotechnol. Rep., 42.","DOI":"10.1016\/j.btre.2024.e00843"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41467-020-15113-2","article-title":"Aptamer-based optical manipulation of protein subcellular localization in cells","volume":"11","author":"Xie","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Li, Y., Liu, R., and Zhao, Z. (2025). Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010109"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1902604","DOI":"10.1002\/adma.201902604","article-title":"Ligand-Installed Nanocarriers toward Precision Therapy","volume":"32","author":"Mi","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12935-024-03295-4","article-title":"Aptamers as an Approach to Targeted Cancer Therapy","volume":"24","author":"Mahmoudian","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., and Zhang, G. (2017). Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081683"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Byun, J. (2021). Recent Progress and Opportunities for Nucleic Acid Aptamers. Life, 11.","DOI":"10.3390\/life11030193"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eabf9180","DOI":"10.1126\/sciadv.abf9180","article-title":"Targeting Alzheimer\u2019s disease with multimodal polypeptide-based nanoconjugates","volume":"7","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Barkat, M.A., Ahmad, F.J., Rahman, M.A., and Ansari, M.A. (2024). Theranostic Application of Nanomedicine in Neurodegenerative Diseases: Current and Future Perspectives. Nanotheranostics for Diagnosis and Therapy, Springer Nature.","DOI":"10.1007\/978-981-97-3115-2"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.colcom.2021.100554","article-title":"Aptamer-nanoconjugates as emerging theranostic systems in neurodegenerative disorders","volume":"46","author":"Aggarwal","year":"2022","journal-title":"Colloid. Interface Sci. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"124151","DOI":"10.1016\/j.ijpharm.2024.124151","article-title":"Posterior eye delivery of angiogenesis-inhibiting RNA nanoparticles via subconjunctival injection","volume":"657","author":"Zhong","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ebenezer, O., Comoglio, P., Wong, G.K.-S., and Tuszynski, J.A. (2023). Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044019"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1039\/D1SM00070E","article-title":"Divalent ligand-monovalent molecule binding","volume":"17","author":"Janssen","year":"2021","journal-title":"Soft Matter"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1093\/nar\/gkac156","article-title":"Programmable manipulation of oligonucleotide-albumin interaction for elongated circulation time","volume":"50","author":"Yang","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacbts.2023.06.013","article-title":"Diagnostic and Therapeutic Aptamers","volume":"9","author":"Lauta","year":"2024","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1021\/acschembio.4c00536","article-title":"Aptamer and N-Degron Ensemble (AptaGron) as a Target Protein Degradation Strategy","volume":"19","author":"Shkel","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.7150\/thno.24015","article-title":"Cascade-amplifying synergistic effects of chemo-photodynamic therapy using ROS-responsive polymeric nanocarriers","volume":"8","author":"Sun","year":"2018","journal-title":"Theranostics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.ymthe.2025.02.047","article-title":"Using aptamers for targeted delivery of RNA therapies","volume":"33","author":"Driscoll","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114816","DOI":"10.1016\/j.addr.2023.114816","article-title":"An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines","volume":"196","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1021\/acs.molpharmaceut.4c00604","article-title":"Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier","volume":"21","author":"Culkins","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102256","DOI":"10.1016\/j.omtn.2024.102256","article-title":"Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress","volume":"35","author":"Dume","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.02.040","article-title":"Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities","volume":"277","author":"Belfiore","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1021\/acsnano.3c09576","article-title":"Aptamer Renaissance for Neurochemical Biosensing","volume":"18","author":"Stuber","year":"2024","journal-title":"ACS Nano"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102373","DOI":"10.1016\/j.omtn.2024.102373","article-title":"Delivering therapeutic RNA into the brain using extracellular vesicles","volume":"35","author":"Shirmast","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1021\/acsnano.2c11675","article-title":"Aptamer Nanoconstructs Crossing Human Blood-Brain Barrier Discovered via Microphysiological System-Based SELEX Technology","volume":"17","author":"Choi","year":"2023","journal-title":"ACS Nano"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/nat.2019.0807","article-title":"Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells","volume":"30","author":"Macdonald","year":"2020","journal-title":"Nucleic Acid. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ozturk, M., Nilsen-Hamilton, M., and Ilgu, M. (2021). Aptamer Applications in Neuroscience. Pharmaceuticals, 14.","DOI":"10.20944\/preprints202111.0100.v1"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ghasemii, K., Darroudi, M., Rahimmanesh, I., Ghomi, M., Hassanpour, M., Sharifi, E., Yousefiasl, S., Ahmadi, S., Zarrabi, A., and Borzacchiello, A. (2022). Advances in aptamer-based drug delivery vehicles for cancer therapy. Biomater. Adv., 140.","DOI":"10.1016\/j.bioadv.2022.213077"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Brylev, V.A., Ryabukhina, E.V., Nazarova, E.V., Samoylenkova, N.S., Gulyak, E.L., Sapozhnikova, K.A., Dzarieva, F.M., Ustinov, A.V., Pronin, I.N., and Usachev, D.Y. (2024). Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111434"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102444","DOI":"10.1016\/j.arr.2024.102444","article-title":"Potential application of aptamers combined with DNA nanoflowers in neurodegenerative diseases","volume":"100","author":"Hang","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"104694","DOI":"10.1016\/j.jddst.2023.104694","article-title":"Strategies facilitating the permeation of nanoparticles through blood-brain barrier: An insight towards the development of brain-targeted drug delivery system","volume":"86","author":"Mishra","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/acs.jmedchem.7b00527","article-title":"Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier","volume":"60","author":"Monaco","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"115302","DOI":"10.1016\/j.addr.2024.115302","article-title":"Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics","volume":"208","author":"Garbayo","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1038\/mtna.2013.26","article-title":"CD28 Aptamers as Powerful Immune Response Modulators","volume":"2","author":"Pastor","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Yadav, P., Ambudkar, S.V., and Rajendra Prasad, N. (2022). Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer. J. Nanobiotechnol., 20.","DOI":"10.1186\/s12951-022-01626-z"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102046","DOI":"10.1016\/j.omtn.2023.102046","article-title":"Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer","volume":"34","author":"Thomas","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1039\/D4NR00207E","article-title":"Role of aptamer technology in extracellular vesicle biology and therapeutic applications","volume":"16","author":"Chowdhury","year":"2024","journal-title":"Nanoscale"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","article-title":"RNA editing: Expanding the potential of RNA therapeutics","volume":"31","author":"Booth","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhang, M.M., Bahal, R., Rasmussen, T.P., Manautou, J.E., and Zhong, X. (2021). The growth of siRNA-based therapeutics: Updated clinical studies. Biochem. Pharmacol., 189.","DOI":"10.1016\/j.bcp.2021.114432"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Seo, K., Hwang, K., Nam, K.M., Kim, M.J., Song, Y.-K., and Kim, C.-Y. (2024). Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma. Pharmaceutics, 16.","DOI":"10.20944\/preprints202404.0167.v1"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcis.2016.12.004","article-title":"Precise Glioblastoma Targeting by AS1411 Aptamer-Functionalized Poly(L-\u03b3-glutamylglutamine)-Paclitaxel Nanoconjugates","volume":"490","author":"Luo","year":"2017","journal-title":"J. Colloid. Interface Sci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chauhan, M., Singh, R.P., Yadav, B., Shekhar, S., Kumar, L., Mehata, A.K., Jhawat, V., Dutt, R., and Garg, V. (2023). Dual-Targeted Transferrin and AS1411 Aptamer Conjugated Micelles for Improved Therapeutic Efficacy and Imaging of Brain Cancer. Colloids Surf. B Biointerfaces, 231.","DOI":"10.1016\/j.colsurfb.2023.113544"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Chauhan, M., Shekhar, S., Yadav, B., Garg, V., Dutt, R., Mehata, A.K., Goswami, P., Koch, B., and Muthu, M.S. (2024). AS1411 Aptamer\/RGD Dual Functionalized Theranostic Chitosan-PLGA Nanoparticles for Brain Cancer Treatment and Imaging. Biomater. Adv., 160.","DOI":"10.1016\/j.bioadv.2024.213833"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Fei, H., Jin, Y., Jiang, N., Zhou, Y., Wei, N., Liu, Y., Miao, J., Zhang, L., Li, R., and Zhang, A. (2024). Gint4.T-siHDGF Chimera-Capped Mesoporous Silica Nanoparticles Encapsulating Temozolomide for Synergistic Glioblastoma Therapy. Biomaterials, 306.","DOI":"10.1016\/j.biomaterials.2024.122479"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2019.08.017","article-title":"Targeted Delivery of C\/EBP\u03b1-saRNA by RNA Aptamers Shows Anti-Tumor Effects in a Mouse Model of Advanced PDAC","volume":"18","author":"Yoon","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"27905","DOI":"10.1021\/acsnano.4c04680","article-title":"AptBCis1, an Aptamer-Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis","volume":"18","author":"Huang","year":"2024","journal-title":"ACS Nano"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Nuzzo, S., Brancato, V., Affinito, A., Salvatore, M., Cavaliere, C., and Condorelli, G. (2020). The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature. Cancers, 12.","DOI":"10.3390\/cancers12082173"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"46290","DOI":"10.1021\/acsami.2c13129","article-title":"Dendrimer-siRNA Conjugates for Targeted Intracellular Delivery in Glioblastoma Animal Models","volume":"14","author":"Liyanage","year":"2022","journal-title":"ACS Appl. Mater. Interfaces."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.2147\/IJN.S133166","article-title":"Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma","volume":"12","author":"Tang","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2062827","DOI":"10.1080\/2162402X.2022.2062827","article-title":"Cell-Directed Aptamer Therapeutic Targeting for Cancers Including Those within the Central Nervous System","volume":"11","author":"Wei","year":"2022","journal-title":"OncoImmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2017.05.002","article-title":"Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance","volume":"31","author":"Livney","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.tranon.2018.02.020","article-title":"Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment","volume":"11","author":"Xu","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/leu.2017.215","article-title":"Targeting Nucleolin for Better Survival in Diffuse Large B-Cell Lymphoma","volume":"32","author":"Jain","year":"2018","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Pavlova, S., Fab, L., Dzarieva, F., Ryabova, A., Revishchin, A., Panteleev, D., Antipova, O., Usachev, D., Kopylov, A., and Pavlova, G. (2024). Unite and Conquer: Association of Two G-Quadruplex Aptamers Provides Antiproliferative and Antimigration Activity for Cells from High-Grade Glioma Patients. Pharmaceuticals, 17.","DOI":"10.3390\/ph17111435"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e175257","DOI":"10.1172\/jci.insight.175257","article-title":"Combination of Locoregional Radio-Therapy with a TIM-3 Aptamer Improves Survival in Diffuse Midline Glioma Models","volume":"9","author":"Lacalle","year":"2024","journal-title":"JCI Insight"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00432-019-02882-7","article-title":"Novel insights into the role of aptamers in the fight against cancer","volume":"145","author":"Maimaitiyiming","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.biomaterials.2010.10.034","article-title":"A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin \u03b1v\u03b23 and tenascin-C proteins","volume":"32","author":"Ko","year":"2011","journal-title":"Biomaterials"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2967\/jnumed.109.069880","article-title":"A Nucleolin-Targeted Multimodal Nanoparticle Imaging Probe for Tracking Cancer Cells Using an Aptamer","volume":"51","author":"Hwang","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.freeradbiomed.2024.11.008","article-title":"NXP031 Restores Memory Function by Dual Effects Degrading A\u03b2 Accumulation and Facilitating Antioxidant Pathway in Alzheimer\u2019s Disease Models","volume":"226","author":"Ju","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Kan, X., Ma, J., Ma, J., Li, D., Li, F., Cao, Y., Huang, C., Li, Y., and Liu, P. (2025). Dual-Targeted TfRA4-DNA1-Ag@AuNPs: An Innovative Radiosensitizer for Enhancing Radiotherapy in Glioblastoma Multiforme. Colloids Surf. B Biointerfaces, 245.","DOI":"10.1016\/j.colsurfb.2024.114328"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Li, D., Zhao, J., Ma, J., Yang, H., Zhang, X., Cao, Y., and Liu, P. (2022). GMT8 Aptamer Conjugated PEGylated Ag@Au Core-Shell Nanoparticles as a Novel Radiosensitizer for Targeted Radiotherapy of Glioma. Colloids Surf. B Biointerfaces, 211.","DOI":"10.1016\/j.colsurfb.2022.112330"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"14314","DOI":"10.1021\/jacs.8b08645","article-title":"Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein","volume":"140","author":"Teng","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/acssensors.3c02167","article-title":"CRISPR-Powered Aptasensor for Diagnostics of Alzheimer\u2019s Disease","volume":"9","author":"Jia","year":"2024","journal-title":"ACS Sens."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10571-019-00741-0","article-title":"Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration","volume":"40","author":"Dar","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.omtn.2024.102251","article-title":"Selection of DNA Aptamers That Prevent the Fibrillization of \u03b1-Synuclein Protein in Cellular and Mouse Models","volume":"35","author":"McConnell","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-323-85538-9.00015-8","article-title":"Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer\u2019s disease and synucleinopathies","volume":"192","author":"Sensi","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3534570","DOI":"10.1155\/2020\/3534570","article-title":"The Antiaggregative and Antiamyloidogenic Properties of Nanoparticles: A Promising Tool for the Treatment and Diagnostics of Neurodegenerative Diseases","volume":"2020","author":"Pichla","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1111\/bph.16399","article-title":"ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis","volume":"181","author":"Marchena","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Aliena-Valero, A., Hern\u00e1ndez-Jim\u00e9nez, M., L\u00f3pez-Morales, M.A., Tamayo-Torres, E., Castell\u00f3-Ruiz, M., Pi\u00f1eiro, D., Rib\u00f3, M., and Salom, J.B. (2024). Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16060741"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Gote, V., Nookala, A.R., Bolla, P.K., and Pal, D. (2021). Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094673"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/acschemneuro.3c00661","article-title":"Isolation and Identification of the High-Affinity DNA Aptamer Target to the Brain-Derived Neurotrophic Factor (BDNF)","volume":"15","author":"Chowdhury","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"ref_129","unstructured":"Shan, L. (2022). Indotricarbocyanine-loaded AS1411 DNA aptamer- and TGN peptide-modified poly(ethylene glycol)-poly(\u03b5-caprolactone) nanoparticles, Molecular Imaging and Contrast Agent Database (MICAD)."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.omtn.2019.05.006","article-title":"RNA Aptamers Targeting Integrin \u03b15\u03b21 as Probes for Cyto- and Histofluorescence in Glioblastoma","volume":"17","author":"Fechter","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1021\/acscentsci.4c00563","article-title":"Delivering DNA Aptamers Across the Blood-Brain Barrier Reveals Heterogeneous Decreased ATP in Different Brain Regions of Alzheimer\u2019s Disease Mouse Models","volume":"10","author":"Banik","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e202200141","DOI":"10.1002\/open.202200141","article-title":"Aptamer-Based Cancer Cell Analysis and Treatment","volume":"11","author":"Wu","year":"2022","journal-title":"ChemistryOpen"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Mikula, E., and Malecka-Baturo, K. (2023). An Overview of the Latest Developments in the Electrochemical Aptasensing of Neurodegenerative Diseases. Coatings, 13.","DOI":"10.3390\/coatings13020235"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/acs.nanolett.7b00159","article-title":"\u201cDNA Origami Traffic Lights\u201d with a Split Aptamer Sensor for a Bicolor Fluorescence Readout","volume":"17","author":"Walter","year":"2017","journal-title":"Nano Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1369\/00221554241272341","article-title":"Histone Acetyl Transferase 1 Is Overexpressed in Poor Prognosis, High-grade Meningeal and Glial Brain Cancers: Immunohistochemical and Aptahistochemical Study","volume":"72","author":"Marin","year":"2024","journal-title":"J. Histochem. Cytochem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.addr.2013.07.012","article-title":"Role of integrated cancer nanomedicine in overcoming drug resistance","volume":"65","author":"Iyer","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1039\/D4NR04228J","article-title":"Enhanced Detection of Brain-Derived Neurotrophic Factor (BDNF) Using a Reduced Graphene Oxide Field-Effect Transistor Aptasensor","volume":"17","author":"Salehirozveh","year":"2025","journal-title":"Nanoscale"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.drudis.2020.12.016","article-title":"Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance","volume":"26","author":"Khot","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Muhammad, M., Liu, C., Yang, G., Shao, C.-S., Xiong, L., Xia, H., Iqbal, J., Zhan, J., Qu, F., and Huang, Q. (2025). Early-stage Alzheimer\u2019s disease profiling in blood achieved by multiplexing aptamer-SERS biosensors. Biosens. Bioelectron., 268.","DOI":"10.1016\/j.bios.2024.116907"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e2311565120","DOI":"10.1073\/pnas.2311565120","article-title":"In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor","volume":"120","author":"Bodily","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Park, J.W., Tian, Y., Kim, S.-T., Park, C., Kim, Y.M., Chung, H.K., Kim, K.M., and Jahng, G.-H. (2024). Oligomeric amyloid-\u03b2 targeted contrast agent for MRI evaluation of Alzheimer\u2019s disease mouse models. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1392729"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2326-6066.CIR-16-0303","article-title":"Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade","volume":"5","author":"Zboralski","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","article-title":"L-RNA Aptamer-Based CXCL12 Inhibition Combined with Radiotherapy in Newly-Diagnosed Glioblastoma: Dose Escalation of the Phase I\/II GLORIA Trial","volume":"15","author":"Giordano","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:32:31Z","timestamp":1760034751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":143,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["pharmaceutics17091106"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17091106","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}